Merck’s ROTATEQ® Reduced Hospitalizations And Emergency Department Visits Due To G9P1A[8] Rotavirus By 100 Percent

The prescribing information for Merck & Co., Inc.’s ROTATEQ® (rotavirus vaccine, live, oral pentavalent), the only vaccine in the U.S. to help prevent rotavirus gastroenteritis in infants and children caused by G1-G4 serotypes, now includes data showing that ROTATEQ reduced hospitalizations and emergency department visits caused by the G9P1A[8] rotavirus serotype, by 100 percent (zero cases were seen in those who received ROTATEQ compared with 14 cases in placebo recipients). [click link for full article]

More: continued here

Filed under: GastroIntestinal / Gastroentorology on December 15th, 2007